GSK chief scientist Barron to leave for U.S. biotech start-up

A view shows GlaxoSmithKline headquarters in London, Britain, January 17, 2022. REUTERS/Hannah McKay

LONDON (Reuters) - GlaxoSmithKline said on Wednesday that Hall Barron will end his position as chief scientific officer in August after less than five years to run a new privately owned start-up biotech company.

Tony Wood will become CSO designate and assume full accountability for Research and Development (R&D) on Aug. 1.

Barron will become a GSK non-executive director on Aug. 1, with additional responsibilities to support R&D, GSK said. He joined GSK in January 2018.

Barron is joining Altos Labs, a new biotech company based in San Francisco, California, focused on the biology of cellular rejuvenation programming with the goal of reversing disease, GSK said.

(Reporting by Josephine Mason; editing by Jason Neely)

Article type: metered
User Type: anonymous web
User Status:
Campaign ID: 1
Cxense type: free
User access status: 3
Join our Telegram channel to get our Evening Alerts and breaking news highlights


Next In Tech News

India's top crypto app CoinSwitch calls for regulatory 'peace, certainty'
Using smartphones to screen for disease
Lawsuit: Tesla autopilot feature accelerated on its own, causing crash
Online romance scams bedevil law enforcement
Power outage: Could a solar storm switch off the world’s technology?
Researchers: Patients should get robotic surgery for quicker recovery
Apple aims to use VR to beat motion sickness in robot cars
SG victims of spoofed work emails suffer losses of over S$70mil, 149 victims in 2022
Victims in SG lose S$466,000 to scammers impersonating ecommerce platform staff
Spotify translating more and more podcasts into multiple languages

Others Also Read